Swedbank AB Has $91.68 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Swedbank AB trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 34.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,271,802 shares of the medical equipment provider's stock after selling 665,200 shares during the quarter. Swedbank AB owned approximately 0.56% of Hologic worth $91,684,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in HOLX. Public Sector Pension Investment Board boosted its holdings in Hologic by 92.5% in the second quarter. Public Sector Pension Investment Board now owns 8,759 shares of the medical equipment provider's stock worth $650,000 after purchasing an additional 4,208 shares during the period. Creative Planning lifted its position in shares of Hologic by 2.4% in the 2nd quarter. Creative Planning now owns 21,813 shares of the medical equipment provider's stock worth $1,620,000 after buying an additional 503 shares during the last quarter. Sunbelt Securities Inc. acquired a new position in shares of Hologic in the 2nd quarter valued at about $37,000. Quarry LP boosted its holdings in shares of Hologic by 323.7% in the 2nd quarter. Quarry LP now owns 1,809 shares of the medical equipment provider's stock valued at $134,000 after buying an additional 1,382 shares during the period. Finally, Sanctuary Advisors LLC bought a new stake in shares of Hologic during the 2nd quarter valued at about $1,212,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.88% of the stock is currently owned by corporate insiders.

Hologic Stock Performance

Shares of HOLX traded up $1.07 on Thursday, reaching $72.48. 411,816 shares of the stock traded hands, compared to its average volume of 2,338,112. The stock's 50-day moving average price is $73.62 and its 200-day moving average price is $78.16. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The firm has a market cap of $16.36 billion, a price-to-earnings ratio of 21.76, a P/E/G ratio of 2.43 and a beta of 0.97. Hologic, Inc. has a 12 month low of $68.61 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period in the prior year, the company posted $0.89 EPS. The company's revenue was up 4.5% compared to the same quarter last year. Equities analysts forecast that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on HOLX. Mizuho decreased their target price on Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Tuesday, November 5th. UBS Group raised their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Royal Bank of Canada raised their price objective on shares of Hologic from $86.00 to $89.00 and gave the company a "sector perform" rating in a research report on Tuesday, November 5th. StockNews.com raised shares of Hologic from a "hold" rating to a "buy" rating in a research report on Thursday, November 14th. Finally, William Blair reaffirmed an "outperform" rating on shares of Hologic in a research note on Monday, January 13th. Seven investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Hologic has an average rating of "Moderate Buy" and a consensus target price of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.